safety of compounded tirzepatide first-new analyses B12-compounded @EliLillyandCo https://t.co/Dl3jAe9l8h Eli Lilly warns against compounding

P.KnippG.LukacovaV.et al (2015)

She continues to struggle with health issues, including ongoing blood clots that require extended use of blood thinners

Immunity 30 , 766775 (2009)

Nicholls, MBBS, PhD, director of the Monash Victorian Heart Institute and professor of cardiology at Monash University in Melbourne, Australia, and colleagues randomly assigned 13,165 participants with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD) to a maximum tolerated dose of 5 mg, 10 mg or 15 mg once-weekly subcutaneous tirzepatide (Mounjaro, Eli Lilly) or 1.5 mg of once-weekly subcutaneous dulaglutide (Trulicity, Eli Lilly) with sham dose escalation